Nivolumab Market- China, Japan, South Korea,Indonesia, Malaysia, UAE, Hong Kong, Singapore, Qatar, Egypt
Nivolumab Market size was valued at USD 10.5 Billion in 2024 and is forecasted to grow at a CAGR of 10.5% from 2026 to 2033, reaching USD 25.4 Billion by 2033. Nivolumab Market : Key Highlights * The non-small cell lung cancer (NSCLC) segment dominates the Nivolumab market,